Overview

Study of Low-Dose Radiotherapy Concurrent Cisplatin/Carboplatin Plus Etoposide With Serplulimab for Patients With ES-SCLC

Status:
Not yet recruiting

Trial end date:
2025-12-30

Target enrollment:

Participant gender:

Summary

This is a Phase II, single arm, multicenter study designed to evaluate the safety and efficacy of low-dose radiotherapy (LDRT) concurrent cisplatin/carboplatin plus etoposide with serplulimab in participants who have extensive-stage small cell lung cancer (ES-SCLC) and are chemotherapy-navïe for their extensive-stage disease.

Phase:

Phase 2

Details

Lead Sponsor:

Sichuan University

Treatments:

Carboplatin
Etoposide